Q3681053 (Q3681053): Difference between revisions
Jump to navigation
Jump to search
(Removed claims) |
(Changed an Item: importing one item from France) |
||||||||||||||
| Property / instance of | |||||||||||||||
| Property / instance of: Kohesio project / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / financed by | |||||||||||||||
| Property / financed by: European Union / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / country | |||||||||||||||
| Property / country: France / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / budget | |||||||||||||||
0.0 Euro
| |||||||||||||||
| Property / budget: 0.0 Euro / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
0.0 Euro
| |||||||||||||||
| Property / EU contribution: 0.0 Euro / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / co-financing rate | |||||||||||||||
59.63 percent
| |||||||||||||||
| Property / co-financing rate: 59.63 percent / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / start time | |||||||||||||||
1 February 2015
| |||||||||||||||
| Property / start time: 1 February 2015 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / end time | |||||||||||||||
23 May 2018
| |||||||||||||||
| Property / end time: 23 May 2018 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / beneficiary name (string) | |||||||||||||||
SAS UROSPHERE | |||||||||||||||
| Property / beneficiary name (string): SAS UROSPHERE / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary | |||||||||||||||
L’objectif de ce projet est d’optimiser les taux de succès des traitements pour les pathologies inflammatoires et les cancers du côlon, de la prostate et de la vessie. (French) | |||||||||||||||
| Property / summary: L’objectif de ce projet est d’optimiser les taux de succès des traitements pour les pathologies inflammatoires et les cancers du côlon, de la prostate et de la vessie. (French) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / intervention field | |||||||||||||||
| Property / intervention field: Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / fund | |||||||||||||||
| Property / fund: European Regional Development Fund / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / programme | |||||||||||||||
| Property / programme: Midi-Pyrénées et Garonne - ERDF/ESF/YEI / rank | |||||||||||||||
Normal rank | |||||||||||||||
Revision as of 15:12, 17 November 2021
Project Q3681053 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3681053 in France |
Statements
0.0 Euro
0 references
0.0 Euro
0 references
59.63 percent
0 references
1 February 2015
0 references
23 May 2018
0 references
SAS UROSPHERE
0 references
L’objectif de ce projet est d’optimiser les taux de succès des traitements pour les pathologies inflammatoires et les cancers du côlon, de la prostate et de la vessie. (French)
0 references
Identifiers
MP0002666
0 references